What is driving volume in IDIA.SW stock today?

Volume is driven by the Phase 2 initiation for IDOR-1117-2520 and recent revenue beats. IDIA.SW stock traded **3,509,366** shares pre-market, near double its average, as traders price clinical and commercial upside.

How does Idorsia's financials support the IDIA.SW stock thesis?

Idorsia shows sequential revenue strength, reporting **CHF 72,241,000.00** for 2025-06-30. However EPS remains negative (TTM **-0.62**). IDIA.SW stock thesis depends on converting clinical progress into commercial revenue to restore positive EPS.

What is Meyka AI's forecast for IDIA.SW stock?

Meyka AI's forecast model projects **CHF 5.62** over 12 months, implying **38.53%** upside from **CHF 4.06**. These projections are model-based and not guarantees; clinical outcomes will drive variance.

What are the main risks to IDIA.SW stock investors?

Main risks include binary clinical trial outcomes, continued negative EPS, and high EV/Revenue multiples (EV/Sales **8.39**). IDIA.SW stock holders should monitor trial readouts, cash runway, and licensing progress.

CH Stocks

Pre-market most active: Idorsia Ltd (IDIA.SW SIX) CHF4.06 Jan 2026: P2 catalyst

ByHuzaifa Zahoor January 9, 2026January 9, 2026

IDIA.SW stock is trading at CHF 4.06 pre-market and ranks among the most active names on the SIX on Jan 2026. Volume of 3,509,366 shares pushed the price after recent trial news and a string of stronger-than-expected revenue prints. Traders are watching clinical readouts and near-term catalysts after Idorsia reported sequential revenue beats and mixed EPS results, making liquidity and volatility higher than the healthcare sector average in Switzerland.